user

DAPAGLIFLOZIN MODULATES ADROPIN SERUM LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC HEART FAILURE

被引：0
|
作者：
Berezin, Alexander [1 ]
Fushtey, Ivan M. [2 ]
Berezin, Alexander A. [2 ]
机构：
[1] State Med Univ, Dept Internal Med, Zaporozhe, Ukraine
[2] Med Acad Postgrad Educ, Dept Internal Med, Zaporozhe, Ukraine
来源：
JOURNAL OF HYPERTENSION | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：E100 / E100
页数：1
相关论文
共 50 条
  • [11] Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
    Alexander A. Berezin
    Ivan M. Fushtey
    Sergii V. Pavlov
    Alexander E. Berezin
    Molecular Biomedicine, 3
  • [12] CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF THE MEDICINAL PRODUCT DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE AND TYPE 2 DIABETES MELLITUS
    V. Zhuravleva, Marina
    V. Gagarina, Julia
    V. Marin, Tatiana
    DIABETES MELLITUS, 2024, 27 (03): : 265 - 276
  • [13] TELMISARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES MELLITUS TYPE 2
    Pavliukovych, N.
    Pavliukovych, O.
    Tryphonyuk, L.
    Kozar, M.
    ATHEROSCLEROSIS, 2019, 287 : E153 - E153
  • [14] The incidence of chronic heart failure in patients with type 2 diabetes mellitus
    Yeshniyazov, N. B.
    Medovchshikov, V. V.
    Tereshchenko, E. A.
    Khasanova, E. R.
    Kobalava, Z. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 253 - 253
  • [15] TELMISARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES MELLITUS TYPE 2
    Pavliukovych, N.
    Pavliukovych, O.
    Kozar, M.
    ATHEROSCLEROSIS, 2022, 355 : E330 - E330
  • [16] Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus
    Filippas-Ntekouan, Sempastian
    Dimou, Aikaterini
    Dafopoulos, Panagiotis
    Kostara, Christina
    Bairaktari, Eleni
    Chasapi, Styliani
    Spyroulias, Georgios
    Koufakis, Theoharis
    Koutsovasilis, Anastasios
    Tsimihodimos, Vasileios
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2024, 24 (01)
  • [17] Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
    Berezin, A. E. Alexander E.
    Berezina, T. A.
    Obradovic, Z.
    Hoppe, U.
    Lichtenauer, M.
    Berezin, O. O.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 182 - 183
  • [18] Predictors of kidney-related outcomes in chronic heart failure patients with concomitant type 2 diabetes mellitus treated with dapagliflozin
    Berezin, A. E. Alexander E.
    Fushtey, I. M.
    Berezina, T. A.
    Obradovic, Z.
    Berezin, O. O.
    Hoppe, U.
    Lichtenauer, M.
    Berezin, A. E.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 170 - 171
  • [19] Dapagliflozin in patients with type 2 diabetes mellitus
    Filippatos, Theodosios D.
    Liberopoulos, Evangelos N.
    Elisaf, Moses S.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 29 - 41
  • [20] An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)
    Yoshihara, Fumiki
    Imazu, Miki
    Hamasaki, Toshimitsu
    Anzai, Toshihisa
    Yasuda, Satoshi
    Ito, Shin
    Yamamoto, Haruko
    Hashimura, Kazuhiko
    Yasumura, Yoshio
    Mori, Kiyoshi
    Watanabe, Masataka
    Asakura, Masanori
    Kitakaze, Masafumi
    CARDIOVASCULAR DRUGS AND THERAPY, 2018, 32 (02) : 183 - 190
12345